Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y241

UPID:
HIG1A_HUMAN

ALTERNATIVE NAMES:
Hypoxia-inducible gene 1 protein; RCF1 homolog A

ALTERNATIVE UPACC:
Q9Y241; Q9UFZ2

BACKGROUND:
The protein HIG1 domain family member 1A, found in mitochondria and known alternatively as Hypoxia-inducible gene 1 protein and RCF1 homolog A, is implicated in the functioning of cytochrome c oxidase (COX, complex IV). This enzyme is essential for the mitochondrial respiratory chain's final step, facilitating the conversion of oxygen into water. Its role is also significant in the assembly of respiratory supercomplexes.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of HIG1 domain family member 1A offers a promising avenue for developing therapeutic interventions, focusing on its integral role in mitochondrial energy metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.